Senseonics Holdings (SENS) Reports In-Line Q1 EPS; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results
May 10, 2022 4:05 PM EDTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2022.
Recent Highlights & Accomplishments:
Received approval from the Food and Drug Administration (FDA) for the Eversense® E3 CGM System (E3), offering industry leading 6-month sensor wear duration, the longest lasting CGM system available Transitioned manufacturing to E3 to enable U.S. commercial launch through our... More